2018
Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
Wang SY, Dang W, Richman I, Mougalian SS, Evans SB, Gross CP. Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal. Journal Of Clinical Oncology 2018, 36: 1619-1627. PMID: 29659329, PMCID: PMC5978470, DOI: 10.1200/jco.2017.76.5941.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCost-Benefit AnalysisFemaleGene Expression ProfilingHumansNeoplasm StagingConceptsCost-effectiveness analysisChemotherapy useBreast cancerEarly-stage breast cancerStudy designIncremental cost-effectiveness ratioODX recurrence scoreHigh-risk patientsLow-risk patientsRisk of biasCost-effectiveness ratioCost-effectiveness estimatesIndustry fundingDistant recurrenceIndustry-funded studiesClinical characteristicsTumor characteristicsRecurrence scoreChemotherapy decisionsScore groupClinical practiceSystematic reviewODXPatientsCancer
2016
Breast Density Notification Legislation and Breast Cancer Stage at Diagnosis: Early Evidence from the SEER Registry
Richman I, Asch SM, Bendavid E, Bhattacharya J, Owens DK. Breast Density Notification Legislation and Breast Cancer Stage at Diagnosis: Early Evidence from the SEER Registry. Journal Of General Internal Medicine 2016, 32: 603-609. PMID: 27844260, PMCID: PMC5442000, DOI: 10.1007/s11606-016-3904-y.Peer-Reviewed Original ResearchConceptsBreast density notification legislationProportion of womenBreast cancer stageCancer stageBreast cancerMetastatic diseaseEnd Results (SEER) Program registryTime of diagnosisInvasive breast cancerBreast density notification lawsSEER registryControl stateDuctal carcinomaInvasive cancerProgram registryAge 40Potential confoundingLimited followSignificant associationIntervention statesDense breastsResultsOur studyCancerDiagnosisEarly detection